For research use only. Not for therapeutic Use.
Befotertinib (Cat No.:I023140) is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to target EGFR-sensitizing mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC). It selectively inhibits mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. Befotertinib has shown promising efficacy in patients with EGFR T790M-positive NSCLC who have progressed on earlier-generation EGFR TKIs. With favorable brain penetration, it also offers potential benefits for patients with central nervous system metastases, making it a valuable option in EGFR-mutant NSCLC therapy.
| CAS Number | 1835667-63-4 |
| Synonyms | N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide |
| Molecular Formula | C29H32F3N7O2 |
| Purity | ≥95% |
| IUPAC Name | N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide |
| InChI | InChI=1S/C29H32F3N7O2/c1-6-27(40)34-22-15-23(26(41-5)16-25(22)38(4)14-13-37(2)3)36-28-33-12-11-21(35-28)20-17-39(18-29(30,31)32)24-10-8-7-9-19(20)24/h6-12,15-17H,1,13-14,18H2,2-5H3,(H,34,40)(H,33,35,36) |
| InChIKey | USOCZVZOXKTJTI-UHFFFAOYSA-N |
| SMILES | CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)CC(F)(F)F)OC |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
